Innovative Product Leadership Mainstay Medical's flagship product, ReActiv8, is the first FDA-approved restorative neurostimulation system for chronic low back pain, positioning the company as a pioneer in neuromodulation therapy and offering a unique value proposition for healthcare providers seeking advanced pain management solutions.

Strong Financial Backing Recent $125 million equity financing led by Gilde Healthcare enhances the company's growth potential and credibility, providing resources for expanding sales efforts, clinical trials, and international market penetration in the neuromodulation space.

Expanding Market Presence Mainstay Medical has recently expanded its offices to Dublin, Ireland, and maintains subsidiaries across Ireland, the US, Germany, Australia, and the Netherlands, enabling targeted regional sales strategies and increased access to diverse healthcare markets.

Clinical Validation & Research Publication of long-term follow-up studies on neuromodulation for low back pain and ongoing clinical trials such as RESTORE reinforce the product's efficacy and safety, providing compelling evidence to engage healthcare providers and clinicians in adopting ReActiv8.

Technology and Innovation Utilizing advanced tech stacks and a focus on research, Mainstay Medical is positioned at the forefront of medical innovation in neurostimulation, offering opportunities for partnerships with healthcare institutions and medical device distributors to expand product adoption.